BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Regulation FD Disclosure


BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Biolase, Inc. will present at the LD Micro Main Event investor conference at the Luxe Sunset Boulevard Hotel in Los Angeles, California on December 7, 2016 and December 8, 2016. During the conference, President and Chief Executive Officer Harold C. Flynn, Jr. will deliver presentations that include written communications comprised of slides. The slides from the presentations are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.

A copy of the slides will be available for viewing and download at for a period of 30 days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation material with investors and from the LD Micro Main Event Conference, dated December 2016.


BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

BIOLASE, INC. (NASDAQ:BIOL) Recent Trading Information

BIOLASE, INC. (NASDAQ:BIOL) closed its last trading session down -0.01 at 1.73 with 81,276 shares trading hands.